A mechanistic analysis of the quantitation of α-hydroxy ketones by the bicinchoninic acid assay

Three hidden talents in one framework: a terephthalic acid-coordinated cupric metal–organic framework with cascade cysteine oxidase- and peroxidase-mimicking activities and stimulus-responsive fluorescence for cysteine sensing

A terephthalic acid-coordinated cupric metal–organic framework with cascade cysteine oxidase- and peroxidase-mimicking activities and stimulus-responsive fluorescence for cysteine sensing.

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma

Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC). The present study used a therapeutic dose of 0.12 mg lenvatinib and/or 10⁴ rat uterine cancer adenocarcinoma (RuCa)-sensitized lymphocytes administered once daily continuously in 7-day cycles. Tumor regression was observed in mice with RCC following treatment with lenvatinib and 10⁴ RuCa-sensitized lymphocytes. MTD was established as once daily administration of 0.18 mg lenvatinib and 10⁶ RuCa-sensitized lymphocytes. The most common treatment-related adverse effects observed were fatigue (40%), mucosal inflammation (30%), proteinuria, diarrhea, vomiting, hypertension and nausea (all 40%). Combination therapy using lenvatinib and cellular immunotherapy enhanced the antitumor effect induced by single treatments and prolonged the survival of mice with RCC compared with either of the single treatments. Treatment with lenvatinib (0.12 mg) combined with 10⁴ RuCa-sensitized lymphocytes was associated with manageable toxicity consistent with individual agents. Further evaluation of this combination therapy in mice with advanced RCC is required. In conclusion, cellular immunotherapy and oncolytic therapy for cancer may be improved by the synergistic effects of lenvatinib and sensitized lymphocytes. In the present study, the inherent antineoplastic and immune stimulatory properties of the two agents were enhanced when used in combination, which may provide a basis for clinical treatment of patients with RCC.

Synthetic Biomaterials from Metabolically Derived Synthons

The utility of metabolic synthons as the building blocks for new biomaterials is based on the early application and success of hydroxy acid based polyesters as degradable sutures and controlled drug delivery matrices. The sheer number of potential monomers derived from the metabolome (e.g., lactic acid, dihydroxyacetone, glycerol, fumarate) gives rise to almost limitless biomaterial structural possibilities, functionality, and performance characteristics, as well as opportunities for the synthesis of new polymers. This review describes recent advances in new chemistries, as well as the inventive use of traditional chemistries, toward the design and synthesis of new polymers. Specific polymeric biomaterials can be prepared for use in varied medical applications (e.g., drug delivery, tissue engineering, wound repair, etc.) through judicious selection of the monomer and backbone linkage.

Protein release from dihydroxyacetone-based poly(carbonate ester) matrices

The release of therapeutics from solid polymer matrices is an important field of study in the area of controlled release. Here we report on the hydrolytic degradation of directly compressed discs comprised of statistically random polycarbonate esters based on lactic acid and dihydroxyacetone. The controlled release of two model proteins, bovine serum albumin and lysozyme, was explored using two percentage loadings (5 and 10 wt.%). A first order release pattern and a trend for faster protein release with increasing dihydroxyacetone content were observed over a time period ranging from 2.5 to 70 days. To analyze the effects of the internal polymer matrix environment on protein stability the enzymatic activity of released lysozyme was monitored. The results show a high level of enzyme activity for the polycarbonate ester ratios with more dihydroxyacetone in the backbone and at least 50% activity over the first month of release from the co-polymer ratios with more lactic acid in the backbone. Modeling of the release kinetics using the Korsmeyer-Peppas model showed a high correlation, indicating that the release of protein is a complex mechanism controlled by protein diffusion through, and erosion of, the co-polymer matrix. The outcomes show that these polycarbonate esters may be useful materials for extended controlled release of proteins.

The highly abundant urinary metabolite urobilin interferes with the bicinchoninic acid assay

Estimation of total protein concentration is an essential step in any protein- or peptide-centric analysis pipeline. This study demonstrates that urobilin, a breakdown product of heme and a major constituent of urine, interferes considerably with the bicinchoninic acid (BCA) assay. This interference is probably due to the propensity of urobilin to reduce cupric ions (Cu(2+)) to cuprous ions (Cu(1+)), thus mimicking the reduction of copper by proteins, which the assay was designed to do. In addition, it is demonstrated that the Bradford assay is more resistant to the influence of urobilin and other small molecules. As such, urobilin has a strong confounding effect on the estimate of total protein concentrations obtained by BCA assay and thus this assay should not be used for urinary protein quantification. It is recommended that the Bradford assay be used instead.